Abzena PLC (LON:ABZA)‘s stock had its “corporate” rating restated by N+1 Singer in a research report issued to clients and investors on Monday, AnalystRatings.Net reports.

Abzena PLC (LON:ABZA) opened at 51.3000 on Monday. The stock’s 50 day moving average price is GBX 60.15 and its 200 day moving average price is GBX 69.70. The stock’s market cap is GBX 50.00 million. Abzena PLC has a 12-month low of GBX 49.00 and a 12-month high of GBX 87.00.

Abzena plc is a life sciences company providing services and technologies. The Company is engaged in the provision of services and technology licenses. The Company consists of PolyTherics and Antitope, which have established a suite of services and technologies that are designed to improve the chances of development of antibodies and proteins with therapeutic benefits. Antitope provides immunogenicity assessment, protein engineering and manufacturing cell line development. The Company’s protein engineering technologies, Composite Human Antibodies and Composite Proteins, are used to create products with less risk of producing an unwanted immune response in patients. PolyTherics specializes in site-specific bioconjugation of drugs to therapeutic antibodies and other targeting proteins, which deliver the drug to specific cells, including cancer cells.

Receive News & Ratings for Abzena PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abzena PLC and related companies with MarketBeat.com's FREE daily email newsletter.